Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ACAD |
---|---|---|
09:32 ET | 8047 | 16.33 |
09:34 ET | 400 | 16.33 |
09:36 ET | 1369 | 16.35 |
09:38 ET | 1843 | 16.35 |
09:39 ET | 500 | 16.34 |
09:41 ET | 760 | 16.36 |
09:43 ET | 440 | 16.36 |
09:45 ET | 1236 | 16.41 |
09:48 ET | 1650 | 16.37 |
09:50 ET | 2973 | 16.4 |
09:52 ET | 1834 | 16.42 |
09:54 ET | 200 | 16.42 |
09:56 ET | 1239 | 16.4 |
09:57 ET | 400 | 16.41 |
09:59 ET | 1216 | 16.36 |
10:01 ET | 2064 | 16.36 |
10:03 ET | 1164 | 16.35 |
10:06 ET | 1075 | 16.3439 |
10:08 ET | 300 | 16.35 |
10:10 ET | 500 | 16.37 |
10:12 ET | 539 | 16.34 |
10:14 ET | 700 | 16.35 |
10:15 ET | 1028 | 16.32 |
10:17 ET | 400 | 16.32 |
10:21 ET | 200 | 16.29 |
10:24 ET | 2409 | 16.28 |
10:26 ET | 2042 | 16.21 |
10:28 ET | 2700 | 16.21 |
10:30 ET | 316 | 16.17 |
10:32 ET | 500 | 16.18 |
10:33 ET | 682 | 16.17 |
10:35 ET | 1338 | 16.15 |
10:37 ET | 5618 | 16.18 |
10:39 ET | 1300 | 16.19 |
10:42 ET | 4169 | 16.2 |
10:44 ET | 100 | 16.22 |
10:46 ET | 1406 | 16.25 |
10:48 ET | 800 | 16.255 |
10:50 ET | 1100 | 16.22 |
10:53 ET | 100 | 16.23 |
10:55 ET | 200 | 16.235 |
10:57 ET | 900 | 16.255 |
11:00 ET | 211 | 16.25 |
11:02 ET | 100 | 16.255 |
11:04 ET | 2199 | 16.23 |
11:06 ET | 1011 | 16.21 |
11:08 ET | 650 | 16.2 |
11:09 ET | 1376 | 16.2 |
11:11 ET | 1619 | 16.25 |
11:13 ET | 521 | 16.29 |
11:15 ET | 1964 | 16.3 |
11:18 ET | 200 | 16.31 |
11:20 ET | 1200 | 16.33 |
11:22 ET | 1311 | 16.34 |
11:24 ET | 1100 | 16.31 |
11:26 ET | 700 | 16.34 |
11:27 ET | 999 | 16.33 |
11:29 ET | 1000 | 16.31 |
11:31 ET | 700 | 16.28 |
11:33 ET | 100 | 16.29 |
11:36 ET | 500 | 16.32 |
11:38 ET | 1132 | 16.345 |
11:40 ET | 800 | 16.37 |
11:42 ET | 2424 | 16.36 |
11:44 ET | 200 | 16.34 |
11:45 ET | 1486 | 16.34 |
11:47 ET | 100 | 16.33 |
11:49 ET | 736 | 16.34 |
11:51 ET | 1300 | 16.37 |
11:54 ET | 200 | 16.36 |
11:56 ET | 500 | 16.36 |
11:58 ET | 300 | 16.36 |
12:00 ET | 524 | 16.35 |
12:03 ET | 2386 | 16.33 |
12:05 ET | 100 | 16.34 |
12:07 ET | 1552 | 16.33 |
12:09 ET | 600 | 16.34 |
12:12 ET | 824 | 16.3 |
12:14 ET | 800 | 16.27 |
12:16 ET | 300 | 16.26 |
12:18 ET | 898 | 16.23 |
12:20 ET | 100 | 16.225 |
12:21 ET | 1100 | 16.24 |
12:25 ET | 2659 | 16.245 |
12:27 ET | 1150 | 16.29 |
12:30 ET | 500 | 16.28 |
12:32 ET | 960 | 16.3 |
12:34 ET | 500 | 16.28 |
12:36 ET | 200 | 16.27 |
12:38 ET | 302 | 16.29 |
12:39 ET | 100 | 16.29 |
12:41 ET | 600 | 16.28 |
12:45 ET | 100 | 16.29 |
12:48 ET | 139 | 16.2875 |
12:50 ET | 100 | 16.29 |
12:52 ET | 200 | 16.29 |
12:54 ET | 600 | 16.3 |
12:56 ET | 300 | 16.3 |
12:57 ET | 500 | 16.31 |
12:59 ET | 632 | 16.315 |
01:01 ET | 1386 | 16.28 |
01:03 ET | 100 | 16.29 |
01:06 ET | 400 | 16.285 |
01:08 ET | 1127 | 16.29 |
01:10 ET | 100 | 16.28 |
01:12 ET | 200 | 16.28 |
01:14 ET | 1700 | 16.28 |
01:15 ET | 700 | 16.28 |
01:17 ET | 700 | 16.28 |
01:19 ET | 200 | 16.27 |
01:21 ET | 500 | 16.27 |
01:24 ET | 2320 | 16.33 |
01:26 ET | 2605 | 16.37 |
01:28 ET | 300 | 16.37 |
01:30 ET | 184 | 16.37 |
01:32 ET | 500 | 16.37 |
01:33 ET | 1908 | 16.36 |
01:35 ET | 960 | 16.37 |
01:37 ET | 708 | 16.39 |
01:39 ET | 400 | 16.39 |
01:42 ET | 1535 | 16.36 |
01:44 ET | 650 | 16.37 |
01:46 ET | 400 | 16.36 |
01:48 ET | 300 | 16.34 |
01:50 ET | 200 | 16.35 |
01:53 ET | 2956 | 16.34 |
01:55 ET | 400 | 16.345 |
01:57 ET | 2668 | 16.34 |
02:00 ET | 200 | 16.35 |
02:02 ET | 2402 | 16.335 |
02:04 ET | 400 | 16.33 |
02:06 ET | 333 | 16.325 |
02:08 ET | 100 | 16.325 |
02:09 ET | 1745 | 16.33 |
02:11 ET | 100 | 16.34 |
02:13 ET | 1222 | 16.345 |
02:15 ET | 1215 | 16.34 |
02:18 ET | 400 | 16.33 |
02:20 ET | 300 | 16.335 |
02:22 ET | 926 | 16.33 |
02:24 ET | 907 | 16.36 |
02:26 ET | 1983 | 16.37 |
02:27 ET | 145 | 16.35 |
02:29 ET | 839 | 16.35 |
02:31 ET | 900 | 16.365 |
02:33 ET | 869 | 16.37 |
02:36 ET | 500 | 16.37 |
02:38 ET | 1099 | 16.38 |
02:42 ET | 1100 | 16.365 |
02:44 ET | 1300 | 16.36 |
02:45 ET | 831 | 16.36 |
02:47 ET | 524 | 16.335 |
02:49 ET | 2202 | 16.3594 |
02:51 ET | 1700 | 16.37 |
02:54 ET | 900 | 16.36 |
02:56 ET | 200 | 16.355 |
02:58 ET | 300 | 16.355 |
03:00 ET | 200 | 16.355 |
03:02 ET | 1262 | 16.37 |
03:03 ET | 700 | 16.355 |
03:05 ET | 1100 | 16.35 |
03:07 ET | 920 | 16.345 |
03:09 ET | 1051 | 16.355 |
03:12 ET | 100 | 16.355 |
03:14 ET | 850 | 16.34 |
03:16 ET | 750 | 16.32 |
03:18 ET | 100 | 16.325 |
03:20 ET | 200 | 16.31 |
03:21 ET | 3001 | 16.32 |
03:23 ET | 1937 | 16.31 |
03:25 ET | 533 | 16.315 |
03:27 ET | 1561 | 16.34 |
03:30 ET | 1168 | 16.34 |
03:32 ET | 1508 | 16.35 |
03:34 ET | 1925 | 16.33 |
03:36 ET | 2114 | 16.3199 |
03:38 ET | 3850 | 16.325 |
03:39 ET | 2053 | 16.315 |
03:41 ET | 996 | 16.29 |
03:43 ET | 690 | 16.285 |
03:45 ET | 830 | 16.27 |
03:48 ET | 7552 | 16.27 |
03:50 ET | 3084 | 16.28 |
03:52 ET | 6061 | 16.265 |
03:54 ET | 6445 | 16.24 |
03:56 ET | 7473 | 16.2 |
03:57 ET | 11839 | 16.21 |
03:59 ET | 249738 | 16.14 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
ACADIA Pharmaceuticals Inc | 2.7B | 89.0x | --- |
Azenta Inc | 2.3B | -17.0x | --- |
PTC Therapeutics Inc | 2.6B | -5.3x | --- |
Guardant Health Inc | 3.1B | -6.2x | --- |
Novavax Inc | 2.1B | -4.8x | --- |
Catalyst Pharmaceuticals Inc | 2.4B | 38.3x | --- |
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.7B |
---|---|
Revenue (TTM) | $890.5M |
Shares Outstanding | 165.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.39 |
EPS | $0.18 |
Book Value | $2.62 |
P/E Ratio | 89.0x |
Price/Sales (TTM) | 3.0 |
Price/Cash Flow (TTM) | 63.7x |
Operating Margin | 2.56% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.